PSTV News & Analysis
2 articles
Market Mood
Plus Therapeutics (PSTV) Appoints Eric Daniels as Chief Development Officer
Plus Therapeutics (PSTV) announced the appointment of Eric Daniels as chief development officer. This leadership change is part of the company's strategy to advance its clinical and regulatory efforts. Eric brings extensive experience in medicine and drug development, which may improve PSTV's competitive position in the market. The appointment is expected to drive progress in Plus Therapeutics' pipeline and operational efficiency.
Read More
Plus Therapeutics (PSTV) REYOBIQ Receives Orphan Drug Status
The FDA has granted orphan drug status to Plus Therapeutics' (PSTV) REYOBIQ. This designation is intended to facilitate the development of treatments for rare diseases and can provide various benefits, including tax credits and market exclusivity. Orphan drug status is crucial for companies seeking to invest in therapies for conditions affecting fewer than 200,000 patients in the U.S. This development may influence investor sentiment and market valuation for Plus Therapeutics (PSTV).
Read More